Method for preventing gastritis using amylin or amylin agonists
CA 2289548 A1 · Owner: Astrazeneca Pharmaceuticals Lp · Inventors: Gedulin, Bronislava; Young, Andrew A.; Beynon, Gareth Wyn
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods for treating or preventing gastritis or gastric injury are disclosed comprising administering a therapeutically effective amount of an amylin or an amylin agonist. Methods are also disclosed for the treatment of conditions for which a non-steroidal anti-inflammatory agent would be indicated comprising , administering an amylin or amylin agonist in conjunction with administering a therapeutically effective amount of a non-steroidal anti-inflammatory agent. Pharmaceutical compositions comprising an amylin or amylin agonist and a nonsteroidal anti-inflammatory agent are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 6, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 6, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 6, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.